Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 5/20 | 0.31 |
| ▸ | CTSD | P07339 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675283 | 0.86 | GRM2 (0.36) | LRRK2GRM2BACE1CTSD | |
| SCHEMBL17675553 | 0.81 | BACE1 (0.35) | LRRK2BACE1CTSD | |
| SCHEMBL17675455 | 0.67 | GRM2 (0.36) | LRRK2GRM2BACE1CTSD | |
| SCHEMBL17675444 | 0.66 | BACE1 (0.37) | BACE1CTSD | |
| SCHEMBL17675652 | 0.66 | BACE1 (0.51) | BACE1CTSD | |
| SCHEMBL17675535 | 0.59 | BACE1 (0.38) | BACE1CTSD | |
| SCHEMBL8023234 | 0.57 | MAOA (0.48) | BACE1CTSD | |
| SCHEMBL446547 | 0.56 | BACE1 (0.49) | BACE1CTSD | |
| SCHEMBL1009552 | 0.56 | MAOA (0.46) | — | |
| SCHEMBL450080 | 0.55 | BACE1 (0.44) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053453-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-08-21 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | LRRK2 78/4885GRM2 2147/4885BACE1 1/4885 |
| US-10053453-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | LRRK2 78/4885GRM2 2147/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.